NBIX supply chain intelligence for Neurocrine Biosciences, Inc.: verified suppliers, customers, debt relationships, acquisitions, and ownership data.
Data compiled by Redley Lamar · ChainSifter Intelligence
| Ticker | Name | Confidence | Evidence |
|---|---|---|---|
| MAZE | Maze Therapeutics, Inc. | 85% | Reciprocal relationship from MAZE graph: Reciprocal relationship from NBIX graph: Reciprocal relationship from MAZE graph: . Potential sales milestones and royalties on net product sales will be reco… |
| LXEO | Lexeo Therapeutics, Inc. | 72% | Reciprocal relationship from LXEO graph: s, obtain marketing approval and ultimately commercialize them. If we are unable to or experience significant delays in doing so, our business will be materia… |
| ORANY | ORANY | 72% | Reciprocal relationship from ORANY graph: Reciprocal relationship from NBIX graph: prepare to bring new therapies to market. Manufacturing and Supply We currently rely on, and intend to continue to r… |
| ORANY | ORANY | 72% | prepare to bring new therapies to market. Manufacturing and Supply We currently rely on, and intend to continue to rely on, third-party manufacturers for the production of INGREZZA, CRENESSITY, and o… |
| TKPHF | Takeda Pharmaceutical Company Limited | 72% | prepare to bring new therapies to market. Manufacturing and Supply We currently rely on, and intend to continue to rely on, third-party manufacturers for the production of INGREZZA, CRENESSITY, and o… |
| TKPHF | Takeda Pharmaceutical Company Limited | 72% | Reciprocal relationship from TKPHF graph: Reciprocal relationship from NBIX graph: prepare to bring new therapies to market. Manufacturing and Supply We currently rely on, and intend to continue to r… |
| VTYX | Ventyx Biosciences Inc | 72% | Reciprocal relationship from VTYX graph: NLRP3 inhibitor. The Company evaluated the ROFN for performance obligations under Accounting Standards Codification (“ASC”) 606, Revenue from Contracts with C… |
| VYGR | Voyager Therapeutics, Inc. | 72% | Reciprocal relationship from VYGR graph: d hazardous substances, including the Occupational Safety and Health Act, the Resource Conservancy and Recovery Act and the Toxic Substances Control Act, affe… |
| XENE | Xenon Pharmaceuticals Inc. | 72% | Reciprocal relationship from XENE graph: Reciprocal relationship from NBIX graph: Reciprocal relationship from XENE graph: Reciprocal relationship from NBIX graph: Reciprocal relationship from XENE g… |
| XENE | Xenon Pharmaceuticals Inc. | 72% | prepare to bring new therapies to market. Manufacturing and Supply We currently rely on, and intend to continue to rely on, third-party manufacturers for the production of INGREZZA, CRENESSITY, and o… |
| Ticker | Name | Confidence | Evidence |
|---|---|---|---|
| CRENESSITY | CRENESSITY | 92% | In addition, CRENESSITY is distributed by one specialty pharmacy provider. |
| SPECIALTY-PHARMACY-PROVIDERS | SPECIALTY-PHARMACY-PROVIDERS | 92% | We have entered into agreements for the distribution of INGREZZA with a limited number of specialty pharmacy providers and distributors. |
| ETON | Eton Pharmaceuticals, Inc. | 72% | cules, peptides, proteins, antibodies, and gene therapy. We launched INGREZZA ® (valbenazine) in the U.S. as the first FDA-approved drug for the treatment of tardive dyskinesia in May 2017 and for th… |
| ETON | Eton Pharmaceuticals, Inc. | 72% | Reciprocal relationship from ETON graph: Reciprocal relationship from NBIX graph: Reciprocal relationship from ETON graph: Reciprocal relationship from NBIX graph: cules, peptides, proteins, antibodi… |
| LXEO | Lexeo Therapeutics, Inc. | 72% | Reciprocal relationship from LXEO graph: ply, if any, could be identified and qualified. We may be unable to find a sufficient alternative supply channel in a reasonable time or on commercially reaso… |
| ORANY | ORANY | 72% | Reciprocal relationship from ORANY graph: Reciprocal relationship from NBIX graph: ons, and to lead the evolving understanding of vesicular monoamine transporter 2 (VMAT2) biology and its role in dis… |
| ORANY | ORANY | 72% | ons, and to lead the evolving understanding of vesicular monoamine transporter 2 (VMAT2) biology and its role in disease. INGREZZA net product sales were $2.51 billion for 2025, $2.31 billion for 202… |
| SPRB | Spruce Biosciences, Inc. | 72% | Reciprocal relationship from SPRB graph: her jurisdictions, all of which could seriously harm our business. 85 Table of Contents Item 1B. Unresolv ed Staff Comments. None. For example, cybersecurity … |
| TKPHF | Takeda Pharmaceutical Company Limited | 72% | Reciprocal relationship from TKPHF graph: Reciprocal relationship from NBIX graph: Reciprocal relationship from TKPHF graph: Reciprocal relationship from NBIX graph: Reciprocal relationship from TKPH… |
| TKPHF | Takeda Pharmaceutical Company Limited | 72% | ons, and to lead the evolving understanding of vesicular monoamine transporter 2 (VMAT2) biology and its role in disease. INGREZZA net product sales were $2.51 billion for 2025, $2.31 billion for 202… |
| VYGR | Voyager Therapeutics, Inc. | 72% | Reciprocal relationship from VYGR graph: d hazardous substances, including the Occupational Safety and Health Act, the Resource Conservancy and Recovery Act and the Toxic Substances Control Act, affe… |
| XENE | Xenon Pharmaceuticals Inc. | 72% | ons, and to lead the evolving understanding of vesicular monoamine transporter 2 (VMAT2) biology and its role in disease. INGREZZA net product sales were $2.51 billion for 2025, $2.31 billion for 202… |
| XENE | Xenon Pharmaceuticals Inc. | 72% | Reciprocal relationship from XENE graph: velopment and marketing efforts of our collaborators. • Our reliance on third parties to manufacture our product candidates may increase the risk that we will… |
| OPERATIONS-NEUROCRINE-BIOSCIENCES-INC | OPERATIONS-NEUROCRINE-BIOSCIENCES-INC | 62% | 68 NEUROCRINE BIOSCIENCES, INC. NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS 1. Business Overview and Summary of Significant Accounting Policies Nature of Operations Neurocrine Biosciences, Inc. an… |
| Instrument | Description | Confidence | Evidence |
|---|---|---|---|
| NBIX-DEBT-11177 | Xbrl Convertible | 90% | xbrl convertible detail from xbrl 2019-12-31. |
| NBIX-DEBT | Debt stack $463.5M | 90% | Market cache reports total debt of $463.5M. |
| Holder | Name | Confidence | Evidence |
|---|---|---|---|
| NBIX-OWNER-BLACKROCK-INC | BlackRock, Inc. | 90% | 13F overlay lists BlackRock, Inc. as top holder; 698 tracked holders. |
| Ticker | Name | Chain Index | Hops | Relationship Types |
|---|---|---|---|---|
| DSGN | Design Therapeutics, Inc. | 100.00 | 2 | |
| ALC | Alcon Inc. | 100.00 | 2 | |
| CYTK | Cytokinetics, Incorporated | 100.00 | 2 | |
| CCEP | Coca-Cola Europacific Partners PLC | 100.00 | 2 | |
| DBVTF | DBV TECHNOLOGIES | 100.00 | 2 | |
| EDIT | Editas Medicine, Inc. | 100.00 | 2 | |
| WHWK | Whitehawk Therapeutics, Inc. | 100.00 | 2 | |
| BIOA | BioAge Labs, Inc. | 100.00 | 2 | |
| CBIO | Crescent Biopharma, Inc. | 100.00 | 2 | |
| CTMX | CytomX Therapeutics, Inc. | 100.00 | 2 | |
| AZN | AstraZeneca PLC | 100.00 | 2 | |
| ANL | Adlai Nortye Ltd. | 100.00 | 2 | |
| CLYM | Climb Bio, Inc. | 100.00 | 2 | |
| DAWN | Day One Biopharmaceuticals Inc | 100.00 | 2 | |
| ANRO | Alto Neuroscience, Inc. | 100.00 | 2 | |
| AXSM | Axsome Therapeutics, Inc. | 100.00 | 2 | |
| CYTOF | Altamira Therapeutics Ltd. | 100.00 | 2 | |
| BLRX | BioLineRx Ltd. | 100.00 | 2 | |
| ALXO | ALX Oncology Holdings Inc. | 100.00 | 2 | |
| ATOS | Atossa Therapeutics, Inc. | 100.00 | 2 |